NEWTON, Mass. and NEW YORK, Sept. 19,
2017 /PRNewswire/ -- Tikun Olam, the world
pioneer in cannabis research, and MariMed
Inc. (OTCQB:MRMD), a preeminent management company in the
U.S. medical cannabis industry, announced an expansion of their
licensing agreement for Tikun Olam products to be grown,
manufactured and sold through MariMed's network of managed and
affiliated licensed facilities throughout the United States.
This new agreement brings Tikun Olam's premium cannabis
products, years of proprietary, peer-reviewed scientific research
and unprecedented clinical data collection to four additional
MMJ-legal U.S. states, its most expansive agreement to date. Tikun
Olam and MariMed's relationship began in 2015 with a pilot program
in Delaware and marked the first
time that U.S. patients had access to the world's only cannabis
strains proven to deliver symptomatic relief for specific
conditions including cancer, PTSD, epilepsy, Crohn's
Disease/Colitis, chronic pain and neuropathy to name a few.
"After the great success of our program in Delaware, MariMed is excited to bring Tikun™
to our expanding national network of legal cannabis production and
dispensary facilities," says Robert
Fireman, CEO of MariMed Inc. "Tikun Olam's empirical data on
clinical effectiveness is unsurpassed, and we look forward to
educating healthcare professionals and offering Tikun's products to
tens of thousands of new patients nationwide."
MariMed will introduce Tikun's exclusive strains and products in
state-of-the-art, regulatory compliant and fully operational
cultivation and medical marijuana dispensaries in Rhode Island, Maryland, Massachusetts and Illinois in 2018. Tikun products will be
available in flower, vape cartridges, topicals, tinctures and
edibles utilizing at least six Tikun™ branded strains, including
its world-renowned Avidekel™ high-CBD strain. In addition to
Delaware, Tikun™ products have
launched in Nevada (March 2017) and are expected to launch
Washington (November 2017).
"Tikun Olam is delighted to expand our relationship with
MariMed," says Tikun CEO Bernard
Sucher. "MariMed utilizes the "best practices" and
standards for cultivation and production and their qualified
distribution channels allow us to bring our proven wellness
products to more U.S. patients than ever before."
About Tikun Olam
Tikun Olam ("repair the world" in
Hebrew) is the world's leading cannabis brand and globally
recognized as the pioneer of modern medical cannabis. Operating as
a commercial venture for over 10 years, Tikun Olam's products have
been used since 2010 in ongoing clinical trials in Israel's regulated medical cannabis market,
treating over 10,000 patients for a variety of symptoms of medical
conditions such as Cancer, PTSD, AIDS, epilepsy, Crohn's
Disease/Colitis, multiple sclerosis, cerebral palsy, chronic pain
and neuropathy. Through this access to patients, medical personnel
and data collection, Tikun Olam has developed multiple proprietary
strains, including the first-ever, high-CBD, "high-less" strain
Avidekel™, its popular high-THC strain Alaska™, and its
"one-to-one" CBD/THC strain Midnight™. Tikun Olam's U.S.
operations, established in 2015 as T.O. Global LLC, is a joint
venture with Tikun Olam Ltd. (Israel). Tikun Olam also operates similar
partnerships in Canada (TSX:
LEAF), Australia, Germany and South
Africa, all in support of its global mission to educate the
traditional medical community and its patients on the applications
of cannabis as a scientifically proven wellness product. Visit
www.tikunolamusa.com, and follow us on Facebook, Twitter, and
Instagram.
About MariMed
MariMed is an industry leading
professional management company in the emerging cannabis industry.
Marimed designs, develops, operates, funds, and optimizes medical
cannabis cultivation, production, and dispensary facilities.
MariMed's team has developed state-of-the-art, regulatory-compliant
legal cannabis facilities in multiple states. These facilities are
models of excellence in horticultural principles, cannabis
production, product development, and dispensary operations. MariMed
is on the forefront of precision-dosed cannabis medicine for the
treatment of specific medical conditions. MariMed's branded
products, such as Kalm Fusion™, are being licensed and distributed
in legal cannabis states across the country. For additional
information, visit www.MarimedAdvisors.com.
Forward-Looking Statements
This release contains
certain forward-looking statements and information relating to
MariMed Inc. (the "Company") that are based on the current beliefs
of the Company's management, as well as assumptions made by, and
information currently available to, the Company. Such statements
reflect the current views of the Company with respect to future
events and are subject to certain assumptions, including those
described in this release. Should one or more of these underlying
assumptions prove incorrect, actual results may vary materially
from those described herein as "should," "could," "anticipate,"
"believe," "intend," "plan," "might," "potentially" or "expect."
The Company does not intend to update these forward-looking
statements.
CONTACTS:
|
|
|
|
Tikun Olam Holding
LLC/
Tikun™
|
MariMed
|
Chief Marketing
Officer
|
Business
Development
|
Stephan
Gardner
|
Jon Levine, CFO,
MariMed
|
sgardner@tikunolam.com
|
jlevine@marimedadvisors.com
|
|
844-244-0200
|
|
|
Media
Relations
|
Investor
Relations
|
Gia Moron, GVM
Communications
|
Ed McGregor/Jody
Burfening, LHA
|
GVM.Communications@yahoo.com
|
emcgregor@lhai.com
|
Tracey Henry / Brenda
Loughery, Type A Media
|
212-838-3777
|
Tracey@type-a-media.com;
Brenda@type-a-media.com
|
|
|
Media Relations
|
|
Julie Shepherd,
Accentuate PR
|
|
Julie@accentuatePR.com
847-275-3643
|
|
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/cannabis-science-pioneer-tikun-olam-expands-partnership-with-marimed-to-bring-branded-cannabis-products-to-more-us-mmj-states-300521768.html
SOURCE Tikun Olam